Access broad B cell diversity to select better antibody lead candidates in just days.
Increase your chances of finding rare functional antibody therapeutic candidates by screening the plasma B cell repertoire using the Berkeley Lights Platform.
Plasma B discovery using the Beacon® optofluidic system bypasses time-consuming and inefficient hybridoma fusion.
Plasma B cells are screened using binding and functional assays to select only the most qualified antibody lead candidates. OptoSeq™BCR enables automated recovery of broad antibody sequence diversity in under a week.
With a NanoPen™chamber volume of only 250 pico liters, reactions are fast and precise. Complete assays in less than 1 hour, then reset your chips to enable the next assay to begin. Better characterization upfront reduces the expense of having to sequence or clone irrelevant non-functional hits.
B cells can be screened from multiple organs (spleen, bone marrow, lymph nodes) and cultured for multiple days in specialized media to enable multiple screens from a single cell sample.
Learn how antibody discovery is changing in today’s therapeutic space. Case studies presented by Abveris highlight accelerated development of next-generation antibody therapeutics.
Discover how you can maximize hit recovery and rapidly down-select blocking antibodies from plasma B cells in a single day.
This 4-page brochure explains how the Beacon platform removes tedious steps from the Antibody Discovery workflow and automates phenotype and genotype screening.